Practical Considerations for Switching to V-Go® for Insulin Delivery in Patients with Type 2 Diabetes (pages 10-15)
Rosemarie Lajara, M.D., Diabetes America, Plano, Texas, and Carla Nikkel, BS, RD, LD, CDE, CDTC
V-Go Disposable Insulin Delivery device (Valeritas, Inc., Bridgewater, N.J.) is a wearable device that delivers a continuous basal rate of insulin, as well as on-demand mealtime dosing. This article examines real-world clinical results in patients with uncontrolled Type 2 diabetes who switched from conventional insulin administration to insulin delivery by V-Go. Clinical insight and practical application for V-Go also are provided.
Equipment — Insulin pumps
David S. H. Bell, M.D., Professor Emeritus, Department of Medicine, University of Alabama Birmingham
There is a small but significant increase in the incidence of the development of diabetes with statins based on non-prospective, non-randomized, non-blinded, retrospective studies. The risk is greatest in those who are predisposed to develop diabetes (i.e., those who have the features of the insulin resistance/metabolic syndrome) and who are exposed to the more powerful statins, whether these statins are hydrophilic or lipophilic.
Drug treatment — Cholesterol-lowering drugs
This column highlights recent clinical trial data and landmark clinical trials to provide readers with relevant information and links for obtaining trial data and articles to facilitate discussions with patients and other providers. It features the results of five trials:
EASL–EASD–EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease
Prediction of First Cardiovascular Disease Event in Type 1 Diabetes Mellitus: The Steno Type 1 Risk Engine
A Long-term, Randomized, Double-blind, Placebo-controlled, Multinational, Multi-centre Trial to Evaluate Cardiovascular and Other Long-term Outcomes with Semaglutide in Subjects with Type 2 Diabetes (SUSTAIN™ 6—Long-term Outcomes)
Phase II Safety and Efficacy Study of Oral ORMD- 0801 in Patients With Type 2 Diabetes Mellitus
EXAMINE Study: Cardiovascular Mortality in Patients With Type 2 Diabetes and Recent Acute Coronary Syndromes From the EXAMINE Trial
Kathleen Wyne, M.D., Ph.D.
The recent updates of the lipid guidelines by multiple societies were consistent in identifying Type 2 Diabetes (T2DM) as a CHD risk equivalent, thereby recommending that everyone with diabetes receive statin therapy but that the intensity of the therapy be guided by level of risk. Primary prevention is focused on those ages 40–75 but can be initiated sooner than age 40 if at increased 10-year risk of a CV event. This leads to the question: When does CV risk begin in T1D? Does CV risk actually begin at age 40, or are there people for whom this risk begins much earlier or even much later?
Complications and comorbidities — Cardiovascular disease